Logo

So Much for New Ideas

Oct 05, 2007

The Wall Street Journal's Health Blog reports that Pfizer named Martin Mackay as the new chief of their struggling R&D program. Jacob Goldstein adds that Mackay, who has been at Pfizer for over ten years, is an odd choice since Pfizer had been looking to bring in fresh blood. Pfizer also announced the launch of a dedicated biotech unit in San Franciso that will be run by Corey Goodman.

Breaking News
The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.